Dapagliflozin Alternatives in Missouri
Compare generic and therapeutic alternatives to Dapagliflozin (dapagliflozin) available at Missouri pharmacies. Save up to 50% on your prescription — no insurance required.
Top Alternatives in Missouri
Metformin
therapeutic
First-line T2D therapy — $8/month, no cardiac indication
Avg cash price: $8/mo
Canagliflozin (Invokana)
therapeutic
First SGLT2 inhibitor approved in the US
Avg cash price: $510/mo
Empagliflozin (Jardiance)
therapeutic
SGLT2 inhibitor with strong heart failure data
Avg cash price: $560/mo
Missouri Prescription Assistance Programs
MO HealthNet (Missouri Medicaid)
Prescription drug coverage for MO HealthNet (Missouri Medicaid) enrollees.
Eligibility: Low-income Missouri residents including children, pregnant women, seniors, and people with disabilities. Missouri voted to expand Medicaid in 2020.
Frequently Asked Questions
Is there a generic for dapagliflozin (Farxiga)?
No generic dapagliflozin is available as of 2025. All SGLT2 inhibitors remain brand-only. Metformin is a $10/month first-line alternative for type 2 diabetes alone.
What makes dapagliflozin unique among SGLT2 inhibitors?
Dapagliflozin (Farxiga) has broad FDA approvals: type 2 diabetes, heart failure with reduced AND preserved ejection fraction, and CKD — making it widely prescribed across cardiology and nephrology.
Is dapagliflozin safe for heart failure patients?
Yes — the DAPA-HF trial showed dapagliflozin significantly reduced cardiovascular death and heart failure hospitalisation. It is one of the four pillars of modern HFrEF therapy.
Can Script Unlock reduce the cost of dapagliflozin?
Without a generic, savings come from competitive brand pricing. Script Unlock pharmacies may offer better cash rates than chain pharmacies — post your script to compare.
Does dapagliflozin cause genital infections?
SGLT2 inhibitors including dapagliflozin increase the risk of genital mycotic infections (thrush) due to increased urine glucose. Good hygiene and prompt treatment if symptoms arise are recommended.